Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Cytosorbents (CTSO) over the last 14 years, with Q2 2025 value amounting to $251110.0.

  • Cytosorbents' Asset Writedowns and Impairment rose 3522.06% to $251110.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $273735.0, marking a year-over-year decrease of 4448.29%. This contributed to the annual value of $333735.0 for FY2024, which is 4910.13% down from last year.
  • Latest data reveals that Cytosorbents reported Asset Writedowns and Impairment of $251110.0 as of Q2 2025, which was up 3522.06% from $1890.0 recorded in Q1 2025.
  • Cytosorbents' 5-year Asset Writedowns and Impairment high stood at $305505.0 for Q1 2022, and its period low was -$16552.0 during Q3 2021.
  • Its 5-year average for Asset Writedowns and Impairment is $110442.0, with a median of $111224.0 in 2023.
  • As far as peak fluctuations go, Cytosorbents' Asset Writedowns and Impairment crashed by 19722.74% in 2021, and later skyrocketed by 414119.23% in 2022.
  • Over the past 5 years, Cytosorbents' Asset Writedowns and Impairment (Quarter) stood at -$6649.0 in 2021, then soared by 3170.84% to $204180.0 in 2022, then decreased by 11.81% to $180064.0 in 2023, then crashed by 88.48% to $20735.0 in 2024, then soared by 1111.04% to $251110.0 in 2025.
  • Its Asset Writedowns and Impairment was $251110.0 in Q2 2025, compared to $1890.0 in Q1 2025 and $20735.0 in Q4 2024.